Physician profile
Ronald Buckman
NPI 1871561092
$13,494.29
in general payments reported to CMS, 2019-2025
38 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 92% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,900 · 2020: $2,370 · 2021: $1,819 · 2022: $1,907 · 2023: $2,292 · 2024: $1,882 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,495 · Education: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,495.01 |
| Education | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,428.24 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Novo Nordisk INC | $1,624.33 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,499.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,171.03 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $1,147.62 | 2019-2024 | Repatha, Prolia, Evenity |
| Abbvie INC. | $1,122.20 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Pfizer INC. | $972.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $937.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $405.18 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.99 | 2019-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $261.58 | 2021-2023 | Korlym |
| Amneal Pharmaceuticals LLC | $256.76 | 2020-2025 | Unithroid |
| Allergan, INC. | $237.20 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $147.35 | 2024 | Jynarque |
| Astellas Pharma US INC | $145.63 | 2024-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Buckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.